Pramipexole dihydrochloride extended release tablets, 0.75 mg, packaged in 30-count bottles, Rx o...

FDA Drug Recall #D-1185-2018 — Class III — September 6, 2018

Recall Summary

Recall Number D-1185-2018
Classification Class III — Low risk
Date Initiated September 6, 2018
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Par Pharmaceutical, Inc.
Location Chestnut Ridge, NY
Product Type Drugs
Quantity 16,207 (bottles of 30 tablets)

Product Description

Pramipexole dihydrochloride extended release tablets, 0.75 mg, packaged in 30-count bottles, Rx only, Manufactured by: Par Pharmaceutical, Chestnut Ridge, NY 10977, NDC 10370-252-11

Reason for Recall

Failed impurities/degradation specifications: Finished product contain a known product impurity about current specification levels.

Distribution Pattern

United States nationwide

Lot / Code Information

Lot #: 29906202, Exp 12/18; 29993102, Exp 2/19; 30366102, 30373103, Exp 4/19; 31940601, Exp 3/20.

Other Recalls from Par Pharmaceutical, Inc.

Recall # Classification Product Date
D-1293-2019 Class I Mycophenolate Mofetil for Injection, USP 500 m... Apr 30, 2019
D-0154-2017 Class II Travoprost Ophthalmic Solution USP, 0.004%, a) ... Oct 5, 2016
D-0121-2017 Class III Gildess FE 1/20 (norethindrone acetate, 1 mg an... Sep 27, 2016
D-0123-2017 Class III Gildess 24 FE 1.5/30 (norethindrone acetate, 1 ... Sep 27, 2016
D-0119-2017 Class III Gildess 1.5/30 (norethindrone acetate, 1.5 mg a... Sep 27, 2016

Frequently Asked Questions

Nitrosamines are probable human carcinogens — they can increase cancer risk with long-term exposure above certain thresholds, but they do not cause immediate harm from taking a single dose. The FDA calculates an acceptable daily intake (ADI) for each nitrosamine compound, and recalls are triggered when levels exceed this threshold. If you have been taking a recalled product, the FDA generally advises against abruptly stopping your medication (especially for critical conditions like blood pressure or diabetes) until you consult your doctor. The incremental cancer risk from short-term exposure is very small.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.